Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee

FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting